There are currently 621 clinical trials in Sacramento, California looking for participants to engage in research studies. Trials are conducted at various facilities, including University of California Davis Comprehensive Cancer Center, University of California, Davis Medical Center, University of California, Davis and Sutter Medical Center Sacramento. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
NCT02000115
Recruiting
The objective of the PORTICO pivotal IDE trial is to evaluate the safety and effectiveness of the St Jude Medical (SJM) Portico Transcatheter Heart Valve and Delivery Systems (Portico) in the treatment of severe symptomatic aortic stenosis via transfemoral and alternative delivery methods in high risk and extreme risk patients.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/24/2023
Locations: Sutter Memorial Hospital, Sacramento, California +1 locations
Conditions: Aortic Valve Stenosis
Register for Updates
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
NCT05451212
Recruiting
Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare but potentially severe disease, in which patients develop pathogenic autoantibodies that specifically target the MuSK protein in the neuromuscular junction. This phase 1 study is being conducted to evaluate the safety of various dosing regimens of an investigational cell therapy, MuSK-CAART, that can be given to patients with anti-MuSK antibody positive Myasthenia Gravis (MuSK MG), who have active disease. Various dosing reg... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: UC Davis, Department of Neurology, Sacramento, California
Conditions: MuSK Myasthenia Gravis
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Mercy Cancer Center - Sacramento, Sacramento, California +1 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
NCT04554914
Recruiting
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.
Gender:
All
Ages:
All
Trial Updated:
10/23/2023
Locations: University of California Davis Comprehensive Cancer Center (Adults and Pediatrics), Sacramento, California
Conditions: Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
Register for Updates
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
NCT02838316
Recruiting
The primary objective of this study is to evaluate the safety of Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) during the 12 months following treatment of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: UC Davis Medical Center, Department of Otolaryngology, Head and Neck Surgery, Sacramento, California
Conditions: Oropharyngeal Dysphagia
Register for Updates
Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)
NCT06103669
Recruiting
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: University of California, Davis, Sacramento, California
Conditions: Breast Cancer, Oligoprogressive, Head and Neck Cancer, Sarcoma, Other Cancer
Register for Updates
Patient-Derived Xenografts to Reduce Cancer Health Disparities
NCT04410302
Recruiting
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Gender:
All
Ages:
Between 21 years and 100 years
Trial Updated:
10/12/2023
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Malignant Neoplasm
Register for Updates
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
NCT05763199
Recruiting
This is a pilot phase, randomized, double-blinded feasibility pilot study of AHCC in participants with ovarian cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Ovarian Epithelial Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
Register for Updates
Use of CGM in Kidney Transplant Recipients
NCT04783441
Recruiting
The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/09/2023
Locations: UC Davis Health, Sacramento, California
Conditions: Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Register for Updates
ABL90 Flex Plus Method Comparison Study_Adults
NCT06078956
Recruiting
The goal of this clinical trial is to validate performance claims for method comparison for the ABL90 FLEX PLUS for pH, pCO2, pO2, cCa2+, cCl-, cK+, cNa+, cGlu, cLac, ctHb, sO2, FO2Hb, FMetHb, FCOHb and FHHb in heparinized whole blood in a Point of Care (POC) setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/09/2023
Locations: UC Davis, Sacramento, California
Conditions: Diagnostic Test
Register for Updates
Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin
NCT05941065
Recruiting
The purpose of this study is to assess the safety of the skin balancing gel cream and examine the effects it has on the skin microbiome of individuals with non-cystic acne prone skin.
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
10/06/2023
Locations: Integrative Skin and Research, Sacramento, California
Conditions: Skin Microboime, Acne
Register for Updates
Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer
NCT04726215
Recruiting
This is a pilot study using [18F]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in [18F]F AraG PET signal before and after CkIT therapy, and to correlate this change in [18F]F AraG PET signal with a radiographic response.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: Sutter Cancer Center, Sacramento, California
Conditions: Non Small Cell Lung Cancer
Register for Updates